SELECT PUBLICATIONS

Boccardo F et al; Intergroup Exemestane Study. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 2005;23(22):5138-47. Abstract

Coombes RC et al. A randomized trial of exemestane after two to three years of tamox­ifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350(11):1081-92. Abstract

Goss PE et al. NCIC CTG MA17: Disease free survival according to estrogen receptor and progesterone receptor status of the primary tumor. San Antonio Breast Cancer Symposium 2005;Abstract 2042.

Goss PE et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97(17):1262-71. Abstract

Goss PE et al. Updated analysis of NCIC CTG MA.17 (letrozole vs placebo to letrozole vs placebo) post unblinding. San Antonio Breast Cancer Symposium 2005;Abstract 16.

Howell A et al; ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365(9453):60-2. Abstract

Ingle JN et al. Analysis of duration of letrozole extended adjuvant therapy as measured by hazard ratios of disease recurrence over time for patients on NCIC CTG MA.17. San Antonio Breast Cancer Symposium 2005;Abstract 17.

Jakesz R et al; ABCSG and the GABG. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366(9484):455-62. Abstract

Jakesz R et al. The benefits of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone-responsive early breast cancer: 5 year-analysis of ABCSG Trial 8. San Antonio Breast Cancer Symposium 2005;Abstract 13.

Jonat W et al. Switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-responsive early breast cancer: A meta-analysis of the ARNO 95 trial, ABCSG Trial 8, and the ITA trial. San Antonio Breast Cancer Symposium 2005;Abstract 18.

Petrek JA et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: A prospective study. J Clin Oncol 2006;24(7):1045-51. Abstract

Petrek JA et al. Incidence, time course and determinants of menstrual bleeding after breast cancer treatments: A prospective study. Proc ASCO 2005;Abstract 538.